TY - JOUR
T1 - Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI
AU - Amiri, Houshang
AU - de Sitter, Alexandra
AU - Bendfeldt, Kerstin
AU - Battaglini, Marco
AU - Gandini Wheeler-Kingshott, Claudia A M
AU - Calabrese, Massimiliano
AU - Geurts, Jeroen J G
AU - Rocca, Maria A
AU - Sastre-Garriga, Jaume
AU - Enzinger, Christian
AU - de Stefano, Nicola
AU - Filippi, Massimo
AU - Rovira, Álex
AU - Barkhof, Frederik
AU - Vrenken, Hugo
AU - MAGNIMS Study Group
A2 - Frederiksen, Jette Lautrup Battistini
PY - 2018
Y1 - 2018
N2 - Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS.
AB - Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS.
KW - Atrophy/pathology
KW - Brain Mapping
KW - Gray Matter/pathology
KW - Humans
KW - Magnetic Resonance Imaging/methods
KW - Multiple Sclerosis/pathology
KW - White Matter/pathology
U2 - 10.1016/j.nicl.2018.04.023
DO - 10.1016/j.nicl.2018.04.023
M3 - Review
C2 - 29984155
SN - 2213-1582
VL - 19
SP - 466
EP - 475
JO - NeuroImage. Clinical
JF - NeuroImage. Clinical
ER -